nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—urinary bladder cancer	0.372	0.679	CbGaD
Afatinib—EGFR—urinary bladder cancer	0.176	0.321	CbGaD
Afatinib—ABCB1—Mitomycin—urinary bladder cancer	0.0368	0.19	CbGbCtD
Afatinib—ABCG2—Fluorouracil—urinary bladder cancer	0.0252	0.13	CbGbCtD
Afatinib—ABCG2—Carboplatin—urinary bladder cancer	0.025	0.129	CbGbCtD
Afatinib—ABCG2—Cisplatin—urinary bladder cancer	0.0214	0.11	CbGbCtD
Afatinib—ABCG2—Etoposide—urinary bladder cancer	0.021	0.108	CbGbCtD
Afatinib—ABCG2—Doxorubicin—urinary bladder cancer	0.0143	0.074	CbGbCtD
Afatinib—ABCG2—Methotrexate—urinary bladder cancer	0.0139	0.0716	CbGbCtD
Afatinib—ABCB1—Gemcitabine—urinary bladder cancer	0.0106	0.0548	CbGbCtD
Afatinib—ABCB1—Cisplatin—urinary bladder cancer	0.0077	0.0398	CbGbCtD
Afatinib—ABCB1—Etoposide—urinary bladder cancer	0.00757	0.0391	CbGbCtD
Afatinib—ABCB1—Doxorubicin—urinary bladder cancer	0.00516	0.0267	CbGbCtD
Afatinib—ABCB1—Methotrexate—urinary bladder cancer	0.005	0.0258	CbGbCtD
Afatinib—EPHA6—prostate gland—urinary bladder cancer	0.00271	0.0502	CbGeAlD
Afatinib—PHKG2—prostate gland—urinary bladder cancer	0.00262	0.0484	CbGeAlD
Afatinib—ERBB2—prostate gland—urinary bladder cancer	0.00235	0.0435	CbGeAlD
Afatinib—ERBB4—prostate gland—urinary bladder cancer	0.00235	0.0435	CbGeAlD
Afatinib—DYRK1A—prostate gland—urinary bladder cancer	0.00226	0.0419	CbGeAlD
Afatinib—EGFR—prostate gland—urinary bladder cancer	0.00199	0.0369	CbGeAlD
Afatinib—HIPK4—female reproductive system—urinary bladder cancer	0.00187	0.0347	CbGeAlD
Afatinib—IRAK1—prostate gland—urinary bladder cancer	0.00176	0.0326	CbGeAlD
Afatinib—ERBB4—epithelium—urinary bladder cancer	0.00173	0.032	CbGeAlD
Afatinib—ERBB2—epithelium—urinary bladder cancer	0.00173	0.032	CbGeAlD
Afatinib—LCK—prostate gland—urinary bladder cancer	0.00172	0.0318	CbGeAlD
Afatinib—ERBB2—smooth muscle tissue—urinary bladder cancer	0.00167	0.0308	CbGeAlD
Afatinib—ERBB2—renal system—urinary bladder cancer	0.0016	0.0297	CbGeAlD
Afatinib—DYRK1A—renal system—urinary bladder cancer	0.00154	0.0286	CbGeAlD
Afatinib—EPHA6—female reproductive system—urinary bladder cancer	0.00148	0.0274	CbGeAlD
Afatinib—PHKG2—female reproductive system—urinary bladder cancer	0.00143	0.0264	CbGeAlD
Afatinib—ERBB2—female reproductive system—urinary bladder cancer	0.00128	0.0238	CbGeAlD
Afatinib—ERBB4—female reproductive system—urinary bladder cancer	0.00128	0.0238	CbGeAlD
Afatinib—IRAK1—smooth muscle tissue—urinary bladder cancer	0.00125	0.0231	CbGeAlD
Afatinib—DYRK1A—female reproductive system—urinary bladder cancer	0.00124	0.0229	CbGeAlD
Afatinib—Vandetanib—SRC—urinary bladder cancer	0.0012	0.433	CrCbGaD
Afatinib—ERBB4—vagina—urinary bladder cancer	0.00116	0.0215	CbGeAlD
Afatinib—LCK—urethra—urinary bladder cancer	0.00115	0.0213	CbGeAlD
Afatinib—BLK—lymph node—urinary bladder cancer	0.0011	0.0203	CbGeAlD
Afatinib—ABL1—prostate gland—urinary bladder cancer	0.000986	0.0182	CbGeAlD
Afatinib—IRAK1—female reproductive system—urinary bladder cancer	0.00096	0.0178	CbGeAlD
Afatinib—LCK—vagina—urinary bladder cancer	0.000847	0.0157	CbGeAlD
Afatinib—PHKG2—lymph node—urinary bladder cancer	0.000835	0.0155	CbGeAlD
Afatinib—ABL1—seminal vesicle—urinary bladder cancer	0.000834	0.0154	CbGeAlD
Afatinib—Vandetanib—EGFR—urinary bladder cancer	0.000804	0.291	CrCbGaD
Afatinib—Gefitinib—EGFR—urinary bladder cancer	0.000764	0.276	CrCbGaD
Afatinib—ERBB2—lymph node—urinary bladder cancer	0.000751	0.0139	CbGeAlD
Afatinib—DYRK1A—lymph node—urinary bladder cancer	0.000723	0.0134	CbGeAlD
Afatinib—ABL1—smooth muscle tissue—urinary bladder cancer	0.000698	0.0129	CbGeAlD
Afatinib—ABL1—renal system—urinary bladder cancer	0.000672	0.0124	CbGeAlD
Afatinib—ABL1—urethra—urinary bladder cancer	0.00066	0.0122	CbGeAlD
Afatinib—EGFR—lymph node—urinary bladder cancer	0.000637	0.0118	CbGeAlD
Afatinib—ABCG2—prostate gland—urinary bladder cancer	0.000622	0.0115	CbGeAlD
Afatinib—IRAK1—lymph node—urinary bladder cancer	0.000562	0.0104	CbGeAlD
Afatinib—LCK—lymph node—urinary bladder cancer	0.000548	0.0101	CbGeAlD
Afatinib—ABL1—female reproductive system—urinary bladder cancer	0.000538	0.00996	CbGeAlD
Afatinib—ABCG2—seminal vesicle—urinary bladder cancer	0.000526	0.00973	CbGeAlD
Afatinib—ABL1—vagina—urinary bladder cancer	0.000487	0.00901	CbGeAlD
Afatinib—ABCG2—urethra—urinary bladder cancer	0.000416	0.0077	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Valrubicin—urinary bladder cancer	0.000352	0.0831	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000352	0.0831	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000352	0.0831	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Valrubicin—urinary bladder cancer	0.000352	0.0831	CbGdCrCtD
Afatinib—ABL1—lymph node—urinary bladder cancer	0.000315	0.00583	CbGeAlD
Afatinib—ABCG2—vagina—urinary bladder cancer	0.000307	0.00568	CbGeAlD
Afatinib—ABCB1—prostate gland—urinary bladder cancer	0.000306	0.00567	CbGeAlD
Afatinib—ERBB2—Doxorubicin—Valrubicin—urinary bladder cancer	0.000271	0.064	CbGdCrCtD
Afatinib—ERBB2—Epirubicin—Valrubicin—urinary bladder cancer	0.000271	0.064	CbGdCrCtD
Afatinib—ABCB1—seminal vesicle—urinary bladder cancer	0.000259	0.0048	CbGeAlD
Afatinib—ABCB1—epithelium—urinary bladder cancer	0.000225	0.00417	CbGeAlD
Afatinib—ABCB1—renal system—urinary bladder cancer	0.000209	0.00387	CbGeAlD
Afatinib—ABCB1—urethra—urinary bladder cancer	0.000205	0.0038	CbGeAlD
Afatinib—ABL1—Epirubicin—Valrubicin—urinary bladder cancer	0.000202	0.0478	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Valrubicin—urinary bladder cancer	0.000202	0.0478	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Valrubicin—urinary bladder cancer	0.000202	0.0478	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Valrubicin—urinary bladder cancer	0.000202	0.0478	CbGdCrCtD
Afatinib—ABCG2—lymph node—urinary bladder cancer	0.000198	0.00367	CbGeAlD
Afatinib—Mouth ulceration—Epirubicin—urinary bladder cancer	0.000187	0.00218	CcSEcCtD
Afatinib—Bladder pain—Epirubicin—urinary bladder cancer	0.000187	0.00218	CcSEcCtD
Afatinib—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.000187	0.00218	CcSEcCtD
Afatinib—Cystitis—Doxorubicin—urinary bladder cancer	0.000184	0.00215	CcSEcCtD
Afatinib—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000183	0.00213	CcSEcCtD
Afatinib—Back pain—Gemcitabine—urinary bladder cancer	0.000182	0.00213	CcSEcCtD
Afatinib—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000182	0.00212	CcSEcCtD
Afatinib—Infection—Thiotepa—urinary bladder cancer	0.000182	0.00212	CcSEcCtD
Afatinib—Urethral disorder—Etoposide—urinary bladder cancer	0.000181	0.00211	CcSEcCtD
Afatinib—ERBB2—Podofilox—Etoposide—urinary bladder cancer	0.00018	0.0427	CbGdCrCtD
Afatinib—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000179	0.00209	CcSEcCtD
Afatinib—Sepsis—Epirubicin—urinary bladder cancer	0.000179	0.00209	CcSEcCtD
Afatinib—Alopecia—Cisplatin—urinary bladder cancer	0.000178	0.00208	CcSEcCtD
Afatinib—Skin disorder—Thiotepa—urinary bladder cancer	0.000178	0.00207	CcSEcCtD
Afatinib—Dry eye—Doxorubicin—urinary bladder cancer	0.000176	0.00206	CcSEcCtD
Afatinib—Malnutrition—Cisplatin—urinary bladder cancer	0.000176	0.00205	CcSEcCtD
Afatinib—Eye disorder—Etoposide—urinary bladder cancer	0.000173	0.00201	CcSEcCtD
Afatinib—Mouth ulceration—Doxorubicin—urinary bladder cancer	0.000173	0.00201	CcSEcCtD
Afatinib—Bladder pain—Doxorubicin—urinary bladder cancer	0.000173	0.00201	CcSEcCtD
Afatinib—Muscle spasms—Cisplatin—urinary bladder cancer	0.000169	0.00197	CcSEcCtD
Afatinib—ABCB1—female reproductive system—urinary bladder cancer	0.000167	0.0031	CbGeAlD
Afatinib—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000167	0.00194	CcSEcCtD
Afatinib—Sepsis—Doxorubicin—urinary bladder cancer	0.000166	0.00193	CcSEcCtD
Afatinib—Cough—Gemcitabine—urinary bladder cancer	0.000164	0.00192	CcSEcCtD
Afatinib—Alopecia—Etoposide—urinary bladder cancer	0.000163	0.00191	CcSEcCtD
Afatinib—Dyspepsia—Thiotepa—urinary bladder cancer	0.000161	0.00188	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000159	0.00186	CcSEcCtD
Afatinib—Decreased appetite—Thiotepa—urinary bladder cancer	0.000159	0.00185	CcSEcCtD
Afatinib—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000158	0.00184	CcSEcCtD
Afatinib—Fatigue—Thiotepa—urinary bladder cancer	0.000158	0.00184	CcSEcCtD
Afatinib—Dysgeusia—Etoposide—urinary bladder cancer	0.000158	0.00184	CcSEcCtD
Afatinib—Renal impairment—Epirubicin—urinary bladder cancer	0.000157	0.00184	CcSEcCtD
Afatinib—Constipation—Thiotepa—urinary bladder cancer	0.000156	0.00182	CcSEcCtD
Afatinib—Back pain—Etoposide—urinary bladder cancer	0.000156	0.00182	CcSEcCtD
Afatinib—Muscle spasms—Etoposide—urinary bladder cancer	0.000155	0.0018	CcSEcCtD
Afatinib—Infection—Gemcitabine—urinary bladder cancer	0.000153	0.00178	CcSEcCtD
Afatinib—ABCB1—vagina—urinary bladder cancer	0.000151	0.0028	CbGeAlD
Afatinib—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000151	0.00176	CcSEcCtD
Afatinib—Infection—Fluorouracil—urinary bladder cancer	0.00015	0.00175	CcSEcCtD
Afatinib—Skin disorder—Gemcitabine—urinary bladder cancer	0.000149	0.00174	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000149	0.00173	CcSEcCtD
Afatinib—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000148	0.00173	CcSEcCtD
Afatinib—Renal impairment—Doxorubicin—urinary bladder cancer	0.000146	0.0017	CcSEcCtD
Afatinib—Body temperature increased—Thiotepa—urinary bladder cancer	0.000145	0.00169	CcSEcCtD
Afatinib—Infection—Cisplatin—urinary bladder cancer	0.000142	0.00166	CcSEcCtD
Afatinib—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000141	0.00164	CcSEcCtD
Afatinib—Cough—Etoposide—urinary bladder cancer	0.00014	0.00164	CcSEcCtD
Afatinib—Dehydration—Epirubicin—urinary bladder cancer	0.000139	0.00162	CcSEcCtD
Afatinib—Skin disorder—Cisplatin—urinary bladder cancer	0.000139	0.00162	CcSEcCtD
Afatinib—Insomnia—Gemcitabine—urinary bladder cancer	0.000139	0.00162	CcSEcCtD
Afatinib—Dry skin—Epirubicin—urinary bladder cancer	0.000137	0.0016	CcSEcCtD
Afatinib—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000137	0.0016	CcSEcCtD
Afatinib—Insomnia—Fluorouracil—urinary bladder cancer	0.000137	0.0016	CcSEcCtD
Afatinib—Hypokalaemia—Epirubicin—urinary bladder cancer	0.000136	0.00159	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000136	0.00159	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000135	0.00157	CcSEcCtD
Afatinib—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000135	0.00157	CcSEcCtD
Afatinib—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000134	0.00156	CcSEcCtD
Afatinib—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000134	0.00156	CcSEcCtD
Afatinib—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000133	0.00155	CcSEcCtD
Afatinib—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000133	0.00155	CcSEcCtD
Afatinib—Fatigue—Gemcitabine—urinary bladder cancer	0.000133	0.00155	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000132	0.00154	CcSEcCtD
Afatinib—Constipation—Gemcitabine—urinary bladder cancer	0.000132	0.00153	CcSEcCtD
Afatinib—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000131	0.00153	CcSEcCtD
Afatinib—Asthenia—Thiotepa—urinary bladder cancer	0.000131	0.00153	CcSEcCtD
Afatinib—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000131	0.00152	CcSEcCtD
Afatinib—Infection—Etoposide—urinary bladder cancer	0.000131	0.00152	CcSEcCtD
Afatinib—Pruritus—Thiotepa—urinary bladder cancer	0.000129	0.00151	CcSEcCtD
Afatinib—Dehydration—Doxorubicin—urinary bladder cancer	0.000129	0.0015	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000129	0.0015	CcSEcCtD
Afatinib—Dyspnoea—Cisplatin—urinary bladder cancer	0.000128	0.00149	CcSEcCtD
Afatinib—Skin disorder—Etoposide—urinary bladder cancer	0.000128	0.00149	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—urinary bladder cancer	0.000127	0.00148	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—urinary bladder cancer	0.000126	0.00147	CcSEcCtD
Afatinib—Diarrhoea—Thiotepa—urinary bladder cancer	0.000125	0.00146	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000125	0.00146	CcSEcCtD
Afatinib—Decreased appetite—Cisplatin—urinary bladder cancer	0.000125	0.00145	CcSEcCtD
Afatinib—Pneumonia—Methotrexate—urinary bladder cancer	0.000124	0.00145	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000124	0.00145	CcSEcCtD
Afatinib—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000124	0.00144	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—urinary bladder cancer	0.000123	0.00144	CcSEcCtD
Afatinib—Infestation—Methotrexate—urinary bladder cancer	0.000123	0.00144	CcSEcCtD
Afatinib—DYRK1A—Idarubicin—Epirubicin—urinary bladder cancer	0.000122	0.0289	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000122	0.0289	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000122	0.0289	CbGdCrCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000122	0.00143	CcSEcCtD
Afatinib—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000122	0.00142	CcSEcCtD
Afatinib—Renal failure—Methotrexate—urinary bladder cancer	0.000121	0.00141	CcSEcCtD
Afatinib—Dizziness—Thiotepa—urinary bladder cancer	0.000121	0.00141	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.00012	0.0014	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—urinary bladder cancer	0.00012	0.0014	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—urinary bladder cancer	0.00012	0.0014	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00012	0.00139	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—urinary bladder cancer	0.000117	0.00137	CcSEcCtD
Afatinib—Dyspnoea—Etoposide—urinary bladder cancer	0.000117	0.00137	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000117	0.00136	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—urinary bladder cancer	0.000116	0.00136	CcSEcCtD
Afatinib—Vomiting—Thiotepa—urinary bladder cancer	0.000116	0.00136	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—urinary bladder cancer	0.000116	0.00135	CcSEcCtD
Afatinib—Infestation—Epirubicin—urinary bladder cancer	0.000115	0.00135	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—urinary bladder cancer	0.000115	0.00135	CcSEcCtD
Afatinib—Rash—Thiotepa—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Afatinib—Dermatitis—Thiotepa—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Afatinib—Headache—Thiotepa—urinary bladder cancer	0.000115	0.00134	CcSEcCtD
Afatinib—Decreased appetite—Etoposide—urinary bladder cancer	0.000114	0.00133	CcSEcCtD
Afatinib—Renal failure—Epirubicin—urinary bladder cancer	0.000113	0.00132	CcSEcCtD
Afatinib—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000113	0.00132	CcSEcCtD
Afatinib—Body temperature increased—Cisplatin—urinary bladder cancer	0.000113	0.00132	CcSEcCtD
Afatinib—Fatigue—Etoposide—urinary bladder cancer	0.000113	0.00132	CcSEcCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000113	0.0268	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000113	0.0268	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000113	0.0268	CbGdCrCtD
Afatinib—Stomatitis—Epirubicin—urinary bladder cancer	0.000113	0.00131	CcSEcCtD
Afatinib—Constipation—Etoposide—urinary bladder cancer	0.000112	0.00131	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000112	0.00131	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000112	0.00131	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000111	0.0013	CcSEcCtD
Afatinib—Asthenia—Gemcitabine—urinary bladder cancer	0.00011	0.00129	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000109	0.00128	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Afatinib—Pruritus—Gemcitabine—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Afatinib—Nausea—Thiotepa—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—urinary bladder cancer	0.000109	0.00127	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—urinary bladder cancer	0.000108	0.00126	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—urinary bladder cancer	0.000107	0.00125	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—urinary bladder cancer	0.000107	0.00125	CcSEcCtD
Afatinib—Infestation—Doxorubicin—urinary bladder cancer	0.000107	0.00125	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000107	0.00125	CcSEcCtD
Afatinib—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000105	0.00123	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—urinary bladder cancer	0.000105	0.00122	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Afatinib—Body temperature increased—Etoposide—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—urinary bladder cancer	0.000104	0.00121	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000103	0.00121	CcSEcCtD
Afatinib—Asthenia—Cisplatin—urinary bladder cancer	0.000103	0.0012	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000102	0.00119	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000102	0.00119	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—urinary bladder cancer	0.000102	0.00118	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000101	0.00118	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—urinary bladder cancer	0.000101	0.00117	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—urinary bladder cancer	0.0001	0.00117	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—urinary bladder cancer	9.98e-05	0.00116	CcSEcCtD
Afatinib—Diarrhoea—Cisplatin—urinary bladder cancer	9.81e-05	0.00114	CcSEcCtD
Afatinib—Alopecia—Methotrexate—urinary bladder cancer	9.79e-05	0.00114	CcSEcCtD
Afatinib—ABCB1—lymph node—urinary bladder cancer	9.79e-05	0.00181	CbGeAlD
Afatinib—Vomiting—Gemcitabine—urinary bladder cancer	9.78e-05	0.00114	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—urinary bladder cancer	9.7e-05	0.00113	CcSEcCtD
Afatinib—Rash—Gemcitabine—urinary bladder cancer	9.7e-05	0.00113	CcSEcCtD
Afatinib—Dermatitis—Gemcitabine—urinary bladder cancer	9.69e-05	0.00113	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—urinary bladder cancer	9.69e-05	0.00113	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—urinary bladder cancer	9.64e-05	0.00112	CcSEcCtD
Afatinib—Headache—Gemcitabine—urinary bladder cancer	9.64e-05	0.00112	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—urinary bladder cancer	9.62e-05	0.00112	CcSEcCtD
Afatinib—Rash—Fluorouracil—urinary bladder cancer	9.54e-05	0.00111	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—urinary bladder cancer	9.53e-05	0.00111	CcSEcCtD
Afatinib—Headache—Fluorouracil—urinary bladder cancer	9.48e-05	0.0011	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	9.47e-05	0.0011	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—urinary bladder cancer	9.44e-05	0.0011	CcSEcCtD
Afatinib—Asthenia—Etoposide—urinary bladder cancer	9.43e-05	0.0011	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	9.42e-05	0.0011	CcSEcCtD
Afatinib—ERBB2—Doxorubicin—Epirubicin—urinary bladder cancer	9.41e-05	0.0223	CbGdCrCtD
Afatinib—Urethral disorder—Doxorubicin—urinary bladder cancer	9.4e-05	0.0011	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—urinary bladder cancer	9.34e-05	0.00109	CcSEcCtD
Afatinib—Back pain—Methotrexate—urinary bladder cancer	9.33e-05	0.00109	CcSEcCtD
Afatinib—Pruritus—Etoposide—urinary bladder cancer	9.29e-05	0.00108	CcSEcCtD
Afatinib—Alopecia—Epirubicin—urinary bladder cancer	9.16e-05	0.00107	CcSEcCtD
Afatinib—Nausea—Gemcitabine—urinary bladder cancer	9.14e-05	0.00107	CcSEcCtD
Afatinib—Vomiting—Cisplatin—urinary bladder cancer	9.12e-05	0.00106	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—urinary bladder cancer	9.08e-05	0.00106	CcSEcCtD
Afatinib—Rash—Cisplatin—urinary bladder cancer	9.04e-05	0.00105	CcSEcCtD
Afatinib—Dermatitis—Cisplatin—urinary bladder cancer	9.03e-05	0.00105	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—urinary bladder cancer	9.02e-05	0.00105	CcSEcCtD
Afatinib—Diarrhoea—Etoposide—urinary bladder cancer	8.99e-05	0.00105	CcSEcCtD
Afatinib—Nausea—Fluorouracil—urinary bladder cancer	8.98e-05	0.00105	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—urinary bladder cancer	8.96e-05	0.00105	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—urinary bladder cancer	8.84e-05	0.00103	CcSEcCtD
Afatinib—Back pain—Epirubicin—urinary bladder cancer	8.73e-05	0.00102	CcSEcCtD
Afatinib—ERBB2—Epirubicin—Doxorubicin—urinary bladder cancer	8.71e-05	0.0206	CbGdCrCtD
Afatinib—Dizziness—Etoposide—urinary bladder cancer	8.69e-05	0.00101	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—urinary bladder cancer	8.67e-05	0.00101	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	8.64e-05	0.00101	CcSEcCtD
Afatinib—Nausea—Cisplatin—urinary bladder cancer	8.52e-05	0.000993	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—urinary bladder cancer	8.47e-05	0.000988	CcSEcCtD
Afatinib—Cough—Methotrexate—urinary bladder cancer	8.41e-05	0.000981	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—urinary bladder cancer	8.4e-05	0.00098	CcSEcCtD
Afatinib—Vomiting—Etoposide—urinary bladder cancer	8.35e-05	0.000974	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—urinary bladder cancer	8.35e-05	0.000973	CcSEcCtD
Afatinib—Rash—Etoposide—urinary bladder cancer	8.28e-05	0.000966	CcSEcCtD
Afatinib—Dermatitis—Etoposide—urinary bladder cancer	8.28e-05	0.000965	CcSEcCtD
Afatinib—Headache—Etoposide—urinary bladder cancer	8.23e-05	0.00096	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—urinary bladder cancer	8.18e-05	0.000953	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.15e-05	0.00095	CcSEcCtD
Afatinib—Back pain—Doxorubicin—urinary bladder cancer	8.08e-05	0.000942	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—urinary bladder cancer	8.03e-05	0.000936	CcSEcCtD
Afatinib—Cough—Epirubicin—urinary bladder cancer	7.87e-05	0.000918	CcSEcCtD
Afatinib—Infection—Methotrexate—urinary bladder cancer	7.82e-05	0.000911	CcSEcCtD
Afatinib—Nausea—Etoposide—urinary bladder cancer	7.8e-05	0.00091	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—urinary bladder cancer	7.72e-05	0.0009	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—urinary bladder cancer	7.64e-05	0.000891	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	7.63e-05	0.000889	CcSEcCtD
Afatinib—Infection—Epirubicin—urinary bladder cancer	7.32e-05	0.000853	CcSEcCtD
Afatinib—Cough—Doxorubicin—urinary bladder cancer	7.29e-05	0.000849	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—urinary bladder cancer	7.22e-05	0.000842	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—urinary bladder cancer	7.15e-05	0.000834	CcSEcCtD
Afatinib—Insomnia—Methotrexate—urinary bladder cancer	7.12e-05	0.00083	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.06e-05	0.000823	CcSEcCtD
Afatinib—ABL1—Idarubicin—Epirubicin—urinary bladder cancer	7.03e-05	0.0166	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—urinary bladder cancer	7.03e-05	0.0166	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—urinary bladder cancer	7.03e-05	0.0166	CbGdCrCtD
Afatinib—Dyspnoea—Methotrexate—urinary bladder cancer	7.02e-05	0.000818	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—urinary bladder cancer	6.93e-05	0.000808	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—urinary bladder cancer	6.84e-05	0.000798	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	6.79e-05	0.000792	CcSEcCtD
Afatinib—Fatigue—Methotrexate—urinary bladder cancer	6.78e-05	0.000791	CcSEcCtD
Afatinib—Infection—Doxorubicin—urinary bladder cancer	6.77e-05	0.000789	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—urinary bladder cancer	6.68e-05	0.000779	CcSEcCtD
Afatinib—Insomnia—Epirubicin—urinary bladder cancer	6.66e-05	0.000777	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—urinary bladder cancer	6.62e-05	0.000772	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—urinary bladder cancer	6.57e-05	0.000765	CcSEcCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—urinary bladder cancer	6.5e-05	0.0154	CbGdCrCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—urinary bladder cancer	6.5e-05	0.0154	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—urinary bladder cancer	6.5e-05	0.0154	CbGdCrCtD
Afatinib—Dyspepsia—Epirubicin—urinary bladder cancer	6.48e-05	0.000756	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—urinary bladder cancer	6.4e-05	0.000746	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.36e-05	0.000741	CcSEcCtD
Afatinib—Fatigue—Epirubicin—urinary bladder cancer	6.35e-05	0.00074	CcSEcCtD
Afatinib—Constipation—Epirubicin—urinary bladder cancer	6.3e-05	0.000734	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—urinary bladder cancer	6.22e-05	0.000725	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—urinary bladder cancer	6.16e-05	0.000719	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—urinary bladder cancer	6.07e-05	0.000708	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—urinary bladder cancer	6e-05	0.000699	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—urinary bladder cancer	5.92e-05	0.000691	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5.88e-05	0.000686	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—urinary bladder cancer	5.87e-05	0.000685	CcSEcCtD
Afatinib—Constipation—Doxorubicin—urinary bladder cancer	5.83e-05	0.000679	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—urinary bladder cancer	5.82e-05	0.000679	CcSEcCtD
Afatinib—Asthenia—Methotrexate—urinary bladder cancer	5.65e-05	0.000658	CcSEcCtD
Afatinib—Pruritus—Methotrexate—urinary bladder cancer	5.57e-05	0.000649	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—urinary bladder cancer	5.39e-05	0.000628	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—urinary bladder cancer	5.38e-05	0.000628	CcSEcCtD
Afatinib—Asthenia—Epirubicin—urinary bladder cancer	5.28e-05	0.000616	CcSEcCtD
Afatinib—Pruritus—Epirubicin—urinary bladder cancer	5.21e-05	0.000607	CcSEcCtD
Afatinib—Dizziness—Methotrexate—urinary bladder cancer	5.2e-05	0.000607	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—urinary bladder cancer	5.04e-05	0.000587	CcSEcCtD
Afatinib—Vomiting—Methotrexate—urinary bladder cancer	5e-05	0.000583	CcSEcCtD
Afatinib—Rash—Methotrexate—urinary bladder cancer	4.96e-05	0.000578	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—urinary bladder cancer	4.96e-05	0.000578	CcSEcCtD
Afatinib—Headache—Methotrexate—urinary bladder cancer	4.93e-05	0.000575	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—urinary bladder cancer	4.89e-05	0.00057	CcSEcCtD
Afatinib—Dizziness—Epirubicin—urinary bladder cancer	4.87e-05	0.000568	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—urinary bladder cancer	4.82e-05	0.000562	CcSEcCtD
Afatinib—Vomiting—Epirubicin—urinary bladder cancer	4.68e-05	0.000546	CcSEcCtD
Afatinib—Nausea—Methotrexate—urinary bladder cancer	4.67e-05	0.000545	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—urinary bladder cancer	4.66e-05	0.000544	CcSEcCtD
Afatinib—Rash—Epirubicin—urinary bladder cancer	4.64e-05	0.000541	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—urinary bladder cancer	4.64e-05	0.000541	CcSEcCtD
Afatinib—Headache—Epirubicin—urinary bladder cancer	4.61e-05	0.000538	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—urinary bladder cancer	4.51e-05	0.000525	CcSEcCtD
Afatinib—Nausea—Epirubicin—urinary bladder cancer	4.37e-05	0.00051	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—urinary bladder cancer	4.33e-05	0.000505	CcSEcCtD
Afatinib—Rash—Doxorubicin—urinary bladder cancer	4.3e-05	0.000501	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—urinary bladder cancer	4.29e-05	0.0005	CcSEcCtD
Afatinib—Headache—Doxorubicin—urinary bladder cancer	4.27e-05	0.000498	CcSEcCtD
Afatinib—Nausea—Doxorubicin—urinary bladder cancer	4.05e-05	0.000472	CcSEcCtD
Afatinib—ERBB4—Signaling Pathways—RHOA—urinary bladder cancer	7.29e-06	6.48e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—urinary bladder cancer	7.25e-06	6.45e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CDKN1A—urinary bladder cancer	7.24e-06	6.44e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EGFR—urinary bladder cancer	7.24e-06	6.43e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TERT—urinary bladder cancer	7.23e-06	6.43e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTEN—urinary bladder cancer	7.23e-06	6.43e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDKN1A—urinary bladder cancer	7.22e-06	6.42e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTEN—urinary bladder cancer	7.2e-06	6.4e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGFR3—urinary bladder cancer	7.19e-06	6.39e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CREBBP—urinary bladder cancer	7.16e-06	6.37e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—EP300—urinary bladder cancer	7.15e-06	6.36e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EGFR—urinary bladder cancer	7.13e-06	6.34e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—urinary bladder cancer	7.11e-06	6.32e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.1e-06	6.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.04e-06	6.26e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NAT2—urinary bladder cancer	7.02e-06	6.24e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—urinary bladder cancer	6.99e-06	6.21e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTP1—urinary bladder cancer	6.98e-06	6.21e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TERT—urinary bladder cancer	6.97e-06	6.2e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EGFR—urinary bladder cancer	6.96e-06	6.19e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDKN1A—urinary bladder cancer	6.96e-06	6.19e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—SRC—urinary bladder cancer	6.96e-06	6.19e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGFR3—urinary bladder cancer	6.95e-06	6.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—urinary bladder cancer	6.94e-06	6.17e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTEN—urinary bladder cancer	6.94e-06	6.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—KRAS—urinary bladder cancer	6.94e-06	6.17e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—MYC—urinary bladder cancer	6.93e-06	6.17e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FGFR3—urinary bladder cancer	6.93e-06	6.16e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EP300—urinary bladder cancer	6.89e-06	6.13e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—KRAS—urinary bladder cancer	6.83e-06	6.08e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—MYC—urinary bladder cancer	6.83e-06	6.07e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EGFR—urinary bladder cancer	6.78e-06	6.03e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—ERBB2—urinary bladder cancer	6.75e-06	6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ESR1—urinary bladder cancer	6.75e-06	6e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—KRAS—urinary bladder cancer	6.74e-06	5.99e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—SRC—urinary bladder cancer	6.7e-06	5.96e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EGFR—urinary bladder cancer	6.68e-06	5.94e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—SRC—urinary bladder cancer	6.68e-06	5.94e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—urinary bladder cancer	6.65e-06	5.92e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—FGFR3—urinary bladder cancer	6.63e-06	5.9e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—KRAS—urinary bladder cancer	6.57e-06	5.85e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—urinary bladder cancer	6.57e-06	5.85e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDKN1A—urinary bladder cancer	6.55e-06	5.82e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTEN—urinary bladder cancer	6.53e-06	5.81e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—KRAS—urinary bladder cancer	6.52e-06	5.8e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL8—urinary bladder cancer	6.5e-06	5.78e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—TYMS—urinary bladder cancer	6.49e-06	5.77e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—urinary bladder cancer	6.49e-06	5.77e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—SRC—urinary bladder cancer	6.44e-06	5.72e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NCOR1—urinary bladder cancer	6.41e-06	5.7e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTM1—urinary bladder cancer	6.41e-06	5.7e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—KRAS—urinary bladder cancer	6.41e-06	5.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL8—urinary bladder cancer	6.4e-06	5.69e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR3—urinary bladder cancer	6.39e-06	5.69e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—S100B—urinary bladder cancer	6.39e-06	5.68e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—urinary bladder cancer	6.36e-06	5.66e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—KRAS—urinary bladder cancer	6.31e-06	5.61e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.26e-06	5.56e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EP300—urinary bladder cancer	6.23e-06	5.54e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—urinary bladder cancer	6.21e-06	5.52e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—KRAS—urinary bladder cancer	6.17e-06	5.48e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—S100B—urinary bladder cancer	6.16e-06	5.47e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—urinary bladder cancer	6.14e-06	5.46e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CREBBP—urinary bladder cancer	6.12e-06	5.44e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—urinary bladder cancer	6.12e-06	5.44e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—urinary bladder cancer	6.07e-06	5.4e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—RRM2—urinary bladder cancer	6.06e-06	5.39e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—SRC—urinary bladder cancer	6.06e-06	5.39e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—RHOA—urinary bladder cancer	6.06e-06	5.39e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—urinary bladder cancer	6.05e-06	5.38e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ERCC2—urinary bladder cancer	6.03e-06	5.36e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—ERBB2—urinary bladder cancer	6e-06	5.33e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—urinary bladder cancer	5.96e-06	5.3e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CREBBP—urinary bladder cancer	5.91e-06	5.26e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—urinary bladder cancer	5.9e-06	5.24e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CREBBP—urinary bladder cancer	5.9e-06	5.24e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—urinary bladder cancer	5.88e-06	5.23e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—urinary bladder cancer	5.88e-06	5.22e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.86e-06	5.21e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—urinary bladder cancer	5.85e-06	5.2e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—urinary bladder cancer	5.84e-06	5.2e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1—urinary bladder cancer	5.84e-06	5.19e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—urinary bladder cancer	5.81e-06	5.17e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—urinary bladder cancer	5.79e-06	5.15e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CDKN1A—urinary bladder cancer	5.77e-06	5.13e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—KRAS—urinary bladder cancer	5.76e-06	5.12e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—urinary bladder cancer	5.75e-06	5.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NCOR1—urinary bladder cancer	5.74e-06	5.11e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—urinary bladder cancer	5.73e-06	5.09e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—urinary bladder cancer	5.67e-06	5.04e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CREBBP—urinary bladder cancer	5.65e-06	5.02e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—urinary bladder cancer	5.64e-06	5.02e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HPGDS—urinary bladder cancer	5.61e-06	4.99e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ENO2—urinary bladder cancer	5.61e-06	4.99e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—urinary bladder cancer	5.59e-06	4.97e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EP300—urinary bladder cancer	5.57e-06	4.95e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—KRAS—urinary bladder cancer	5.55e-06	4.94e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—urinary bladder cancer	5.54e-06	4.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NCOR1—urinary bladder cancer	5.54e-06	4.92e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—KRAS—urinary bladder cancer	5.53e-06	4.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EP300—urinary bladder cancer	5.49e-06	4.88e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—urinary bladder cancer	5.48e-06	4.87e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—urinary bladder cancer	5.45e-06	4.84e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTT1—urinary bladder cancer	5.44e-06	4.84e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CREBBP—urinary bladder cancer	5.44e-06	4.84e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—urinary bladder cancer	5.43e-06	4.83e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SRC—urinary bladder cancer	5.42e-06	4.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—urinary bladder cancer	5.36e-06	4.77e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RHOA—urinary bladder cancer	5.35e-06	4.76e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SRC—urinary bladder cancer	5.34e-06	4.75e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—KRAS—urinary bladder cancer	5.33e-06	4.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL8—urinary bladder cancer	5.32e-06	4.73e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—urinary bladder cancer	5.31e-06	4.72e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—urinary bladder cancer	5.24e-06	4.66e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDKN1A—urinary bladder cancer	5.12e-06	4.56e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—ERBB2—urinary bladder cancer	5.12e-06	4.56e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—urinary bladder cancer	5.11e-06	4.55e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—RHOA—urinary bladder cancer	5.11e-06	4.54e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.1e-06	4.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—urinary bladder cancer	5.08e-06	4.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TERT—urinary bladder cancer	5.06e-06	4.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—KRAS—urinary bladder cancer	5.02e-06	4.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ERBB2—urinary bladder cancer	4.95e-06	4.4e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ERBB2—urinary bladder cancer	4.94e-06	4.39e-05	CbGpPWpGaD
Afatinib—LCK—Disease—RHOA—urinary bladder cancer	4.92e-06	4.38e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—urinary bladder cancer	4.9e-06	4.35e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TERT—urinary bladder cancer	4.88e-06	4.34e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EP300—urinary bladder cancer	4.88e-06	4.34e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MYC—urinary bladder cancer	4.86e-06	4.32e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MYC—urinary bladder cancer	4.78e-06	4.25e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—urinary bladder cancer	4.75e-06	4.22e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—urinary bladder cancer	4.74e-06	4.22e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—ERBB2—urinary bladder cancer	4.73e-06	4.21e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—urinary bladder cancer	4.72e-06	4.19e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—urinary bladder cancer	4.7e-06	4.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL8—urinary bladder cancer	4.7e-06	4.18e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—urinary bladder cancer	4.68e-06	4.16e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR3—urinary bladder cancer	4.65e-06	4.13e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—urinary bladder cancer	4.64e-06	4.13e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—urinary bladder cancer	4.62e-06	4.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—urinary bladder cancer	4.6e-06	4.09e-05	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—urinary bladder cancer	4.56e-06	4.05e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—urinary bladder cancer	4.53e-06	4.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—urinary bladder cancer	4.52e-06	4.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—urinary bladder cancer	4.51e-06	4.01e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—urinary bladder cancer	4.49e-06	3.99e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—urinary bladder cancer	4.49e-06	3.99e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR3—urinary bladder cancer	4.48e-06	3.98e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—urinary bladder cancer	4.47e-06	3.98e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—urinary bladder cancer	4.46e-06	3.96e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—urinary bladder cancer	4.42e-06	3.93e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—urinary bladder cancer	4.42e-06	3.93e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—urinary bladder cancer	4.38e-06	3.89e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—urinary bladder cancer	4.38e-06	3.89e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—urinary bladder cancer	4.37e-06	3.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—urinary bladder cancer	4.35e-06	3.87e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—urinary bladder cancer	4.26e-06	3.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—urinary bladder cancer	4.25e-06	3.78e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.23e-06	3.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—urinary bladder cancer	4.22e-06	3.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—urinary bladder cancer	4.22e-06	3.75e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—urinary bladder cancer	4.21e-06	3.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—urinary bladder cancer	4.17e-06	3.7e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—urinary bladder cancer	4.16e-06	3.7e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—urinary bladder cancer	4.05e-06	3.6e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—urinary bladder cancer	4.04e-06	3.59e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—urinary bladder cancer	4.03e-06	3.59e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—urinary bladder cancer	4.03e-06	3.58e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—urinary bladder cancer	4.01e-06	3.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—urinary bladder cancer	3.99e-06	3.55e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—urinary bladder cancer	3.96e-06	3.52e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—urinary bladder cancer	3.93e-06	3.49e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—urinary bladder cancer	3.93e-06	3.49e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—urinary bladder cancer	3.92e-06	3.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—urinary bladder cancer	3.91e-06	3.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—urinary bladder cancer	3.9e-06	3.47e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—urinary bladder cancer	3.9e-06	3.46e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—urinary bladder cancer	3.89e-06	3.46e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—urinary bladder cancer	3.85e-06	3.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—urinary bladder cancer	3.81e-06	3.39e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—urinary bladder cancer	3.81e-06	3.39e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—urinary bladder cancer	3.77e-06	3.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—urinary bladder cancer	3.76e-06	3.35e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—urinary bladder cancer	3.76e-06	3.34e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—urinary bladder cancer	3.74e-06	3.33e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—urinary bladder cancer	3.71e-06	3.3e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—urinary bladder cancer	3.67e-06	3.26e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—urinary bladder cancer	3.62e-06	3.22e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—urinary bladder cancer	3.6e-06	3.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RHOA—urinary bladder cancer	3.58e-06	3.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—urinary bladder cancer	3.51e-06	3.12e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—urinary bladder cancer	3.51e-06	3.12e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOR1—urinary bladder cancer	3.47e-06	3.08e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—urinary bladder cancer	3.47e-06	3.08e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RHOA—urinary bladder cancer	3.45e-06	3.07e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—urinary bladder cancer	3.43e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—urinary bladder cancer	3.42e-06	3.04e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—urinary bladder cancer	3.35e-06	2.98e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—urinary bladder cancer	3.35e-06	2.98e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—urinary bladder cancer	3.34e-06	2.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—urinary bladder cancer	3.32e-06	2.95e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—urinary bladder cancer	3.31e-06	2.95e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—urinary bladder cancer	3.26e-06	2.9e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—urinary bladder cancer	3.24e-06	2.88e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—urinary bladder cancer	3.23e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—urinary bladder cancer	3.23e-06	2.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—urinary bladder cancer	3.19e-06	2.84e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—urinary bladder cancer	3.16e-06	2.81e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—urinary bladder cancer	3.15e-06	2.8e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—urinary bladder cancer	3.14e-06	2.79e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—urinary bladder cancer	3.12e-06	2.77e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—urinary bladder cancer	3.1e-06	2.75e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.06e-06	2.73e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—urinary bladder cancer	3.03e-06	2.69e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—urinary bladder cancer	3.01e-06	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—urinary bladder cancer	3e-06	2.67e-05	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—urinary bladder cancer	2.98e-06	2.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—urinary bladder cancer	2.93e-06	2.6e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—urinary bladder cancer	2.89e-06	2.57e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—urinary bladder cancer	2.88e-06	2.56e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—urinary bladder cancer	2.85e-06	2.54e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—urinary bladder cancer	2.84e-06	2.53e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—urinary bladder cancer	2.83e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—urinary bladder cancer	2.82e-06	2.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—urinary bladder cancer	2.82e-06	2.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—urinary bladder cancer	2.76e-06	2.45e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—urinary bladder cancer	2.75e-06	2.44e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—urinary bladder cancer	2.74e-06	2.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—urinary bladder cancer	2.73e-06	2.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—urinary bladder cancer	2.72e-06	2.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—urinary bladder cancer	2.69e-06	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—urinary bladder cancer	2.63e-06	2.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—urinary bladder cancer	2.62e-06	2.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—urinary bladder cancer	2.6e-06	2.31e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—urinary bladder cancer	2.54e-06	2.26e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—urinary bladder cancer	2.52e-06	2.24e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—urinary bladder cancer	2.49e-06	2.21e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—urinary bladder cancer	2.39e-06	2.12e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—urinary bladder cancer	2.35e-06	2.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—urinary bladder cancer	2.26e-06	2.01e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—urinary bladder cancer	2.21e-06	1.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—urinary bladder cancer	2.17e-06	1.93e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—urinary bladder cancer	2.09e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.95e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—urinary bladder cancer	1.93e-06	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—urinary bladder cancer	1.86e-06	1.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—urinary bladder cancer	1.84e-06	1.64e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—urinary bladder cancer	1.78e-06	1.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.7e-06	1.52e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—urinary bladder cancer	1.63e-06	1.45e-05	CbGpPWpGaD
